Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Salivary Gland Carcinoma: early-phase trial registry
1 of 3 indexed Metastatic Salivary Gland Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Metastatic Salivary Gland Carcinoma: 3 US clinical trials tracked, 1 recruiting.
Metastatic Salivary Gland Carcinoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is NRG Oncology, running 1 of these trials.
Enrollment posture brief
Registry condition metastatic-salivary-gland-carcinoma
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Metastatic Salivary Gland Carcinoma lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Salivary Gland Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Salivary Gland Carcinoma is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
NCT05408845
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Mayo Clinic
NCT04895735
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
National Cancer Institute (NCI)
NCT05669664
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Salivary Gland Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Salivary Gland Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Salivary Gland Carcinoma page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Metastatic Salivary Gland Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- NRG Oncology sponsors the most Metastatic Salivary Gland Carcinoma trials on record, review their full trial history before evaluating a specific study. See NRG Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Salivary Gland Carcinoma condition card totals 3 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.